OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OSRH$0.6459

OSR Holdings Inc

Biotechnology & Medical ResearchVerified

OSR Holdings Inc exhibits a highly leveraged capital structure with a debt-to-equity ratio of 0.06, indicating minimal reliance on debt financing. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.16, suggesting significant short-term liquidity constraints. The price-to-book ratio of 0.27 and price-to-tangible-book ratio of 0.27 further indicate that the company's market value is significantly below its book value, reflecting poor investor sentiment or asset impairment. Profitability metrics are severely negative, with a return on equity of -0.232 and a return on assets of -0.1052, both well below industry norms. The company reported a net loss of $18.01 million and an operating loss of $18.34 million, indicating a lack of operational efficiency and revenue generation. Gross profit of $592,910 is minimal relative to total revenue of $2.91 million, suggesting high cost structures or low pricing power. Geographically and segment-wise, OSR Holdings Inc's revenue concentration is not disclosed in the available data. However, the company's exposure to the healthcare diagnostics industry implies a high degree of specialization, with potential risks tied to regulatory changes and technological obsolescence. The absence of detailed segment reporting limits the ability to assess diversification or growth drivers within the business. The company's growth trajectory is negative, with no clear signs of improvement in the near term. Analysts have assigned a mean price target of $10.00, which is significantly higher than the current market price of $0.64, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest limited confidence in the company's ability to deliver returns. The operating cash flow of -$4.33 million and free cash flow of -$17.93 million indicate a cash burn rate that could threaten the company's solvency if not addressed. Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, but the company's capital structure and financial performance suggest a potential need for equity financing in the future, which could dilute existing shareholders. The absence of capital expenditures and the negative operating cash flow further underscore the company's financial instability. Recent events, including the lack of positive analyst sentiment and the absence of disclosed capital expenditures, suggest a challenging operating environment. The company's financial performance and risk profile indicate a need for significant operational and strategic improvements to restore investor confidence and achieve profitability.

30-day price · OSRH(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyOSR Holdings Inc
TickerOSRH.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. OSR Holdings Inc is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic products and services.

Classification. OSR Holdings Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

OSR Holdings Inc exhibits a highly leveraged capital structure with a debt-to-equity ratio of 0.06, indicating minimal reliance on debt financing. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.16, suggesting significant short-term liquidity constraints. The price-to-book ratio of 0.27 and price-to-tangible-book ratio of 0.27 further indicate that the company's market value is significantly below its book value, reflecting poor investor sentiment or asset impairment. Profitability metrics are severely negative, with a return on equity of -0.232 and a return on assets of -0.1052, both well below industry norms. The company reported a net loss of $18.01 million and an operating loss of $18.34 million, indicating a lack of operational efficiency and revenue generation. Gross profit of $592,910 is minimal relative to total revenue of $2.91 million, suggesting high cost structures or low pricing power. Geographically and segment-wise, OSR Holdings Inc's revenue concentration is not disclosed in the available data. However, the company's exposure to the healthcare diagnostics industry implies a high degree of specialization, with potential risks tied to regulatory changes and technological obsolescence. The absence of detailed segment reporting limits the ability to assess diversification or growth drivers within the business. The company's growth trajectory is negative, with no clear signs of improvement in the near term. Analysts have assigned a mean price target of $10.00, which is significantly higher than the current market price of $0.64, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest limited confidence in the company's ability to deliver returns. The operating cash flow of -$4.33 million and free cash flow of -$17.93 million indicate a cash burn rate that could threaten the company's solvency if not addressed. Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, but the company's capital structure and financial performance suggest a potential need for equity financing in the future, which could dilute existing shareholders. The absence of capital expenditures and the negative operating cash flow further underscore the company's financial instability. Recent events, including the lack of positive analyst sentiment and the absence of disclosed capital expenditures, suggest a challenging operating environment. The company's financial performance and risk profile indicate a need for significant operational and strategic improvements to restore investor confidence and achieve profitability.
Key takeaways
  • OSR Holdings Inc is operating at a significant loss, with a net loss of $18.01 million and an operating loss of $18.34 million.
  • The company's liquidity position is weak, with a current ratio of 0.16 and a negative net cash position.
  • Profitability metrics are severely negative, with a return on equity of -0.232 and a return on assets of -0.1052.
  • Analysts have assigned a mean price target of $10.00, but the lack of strong buy recommendations suggests limited confidence in the company's future performance.
  • The company's capital structure and financial performance indicate a potential need for equity financing, which could dilute existing shareholders.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$2.9M
Gross profit$592.9k
Operating income-$18.3M
Net income-$18.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.3M
CapEx-$176.4k
Free cash flow-$17.9M
Total assets$171.2M
Total liabilities$93.6M
Total equity$77.6M
Cash & equivalents
Long-term debt$4.3M
Valuation
Market price$0.64
Market cap$21.2M
Enterprise value$25.5M
P/E
Reported non-GAAP P/E
EV/Revenue8.8
EV/Op income
EV/OCF
P/B0.3
P/Tangible book0.3
Tangible book$77.6M
Net cash-$4.3M
Current ratio0.2
Debt/Equity0.1
ROA-10.5%
ROE-23.2%
Cash conversion24.0%
CapEx/Revenue-6.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricOSRHActivity
Op margin-631.0%-227.5% medp25 -1250.6% · p75 -3.5%below median
Net margin-619.8%-194.5% medp25 -1233.8% · p75 0.8%below median
Gross margin20.4%53.0% medp25 25.9% · p75 75.7%bottom quartile
CapEx / revenue-6.1%-8.2% medp25 -35.2% · p75 -2.5%above median
Debt / equity6.0%1.2% medp25 0.0% · p75 17.4%above median
Observations
IR observations
Mean price target10.00 USD
Median price target10.00 USD
High price target10.00 USD
Low price target10.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Last actual EPS-0.92 USD
Last actual revenue2,905,810 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 22:45 UTC#6f6bc9c3
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:28 UTCJob: 6f4447bc